Analysis
Commercial Influence in Health: from Transparency to Independence
Pathways to independence: towards producing and using trustworthy evidence
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l6576 (Published 03 December 2019) Cite this as: BMJ 2019;367:l6576Commercial influence in health: from transparency to independence
Click here to read the complete collection
Please sign our call to action
Your opportunity to support greater independence from commercial interests in healthcare and share your thoughts and ideas about how this can be achieved.
Related articles
- Research Published: 19 March 2010; BMJ 340 doi:10.1136/bmj.c1344
- Editorial Published: 28 September 2016; BMJ 354 doi:10.1136/bmj.i5191
- Analysis Published: 17 May 2018; BMJ 361 doi:10.1136/bmj.k1039
- Editorial Published: 16 April 2019; BMJ 365 doi:10.1136/bmj.l1706
- Research Published: 17 January 2017; BMJ 356 doi:10.1136/bmj.i6770
- Letter Published: 20 January 2020; BMJ 368 doi:10.1136/bmj.m165
- Letter Published: 21 January 2020; BMJ 368 doi:10.1136/bmj.m206
- Letter Published: 21 January 2020; BMJ 368 doi:10.1136/bmj.m208
- Letter Published: 09 March 2020; BMJ 368 doi:10.1136/bmj.m807
- Letter Published: 09 March 2020; BMJ 368 doi:10.1136/bmj.m819
- Research Published: 27 May 2020; BMJ 369 doi:10.1136/bmj.m1505
- Views & Reviews Published: 23 November 2020; BMJ 371 doi:10.1136/bmj.m4544
- Editor's Choice Published: 03 December 2020; BMJ 371 doi:10.1136/bmj.m4701
- Feature Published: 07 December 2020; BMJ 371 doi:10.1136/bmj.m4601
- Analysis Published: 27 July 2021; BMJ 374 doi:10.1136/bmj.n1657
- Analysis Published: 19 September 2023; BMJ 382 doi:10.1136/bmj-2023-076173
See more
- Stigma is stopping an evidence based response to drug overdose deaths in the UKBMJ August 09, 2023, 382 e074934; DOI: https://doi.org/10.1136/bmj-2023-074934
- Use and misuse of research: Canada’s response to covid-19 and its health inequalitiesBMJ July 24, 2023, 382 e075666; DOI: https://doi.org/10.1136/bmj-2023-075666
- Screening for depression and anxiety in general practiceBMJ July 17, 2023, 382 p1615; DOI: https://doi.org/10.1136/bmj.p1615
- Tackling the erosion of compassion in acute mental health servicesBMJ July 04, 2023, 382 e073055; DOI: https://doi.org/10.1136/bmj-2022-073055
- Detransition needs further understanding, not controversyBMJ June 14, 2023, 381 e073584; DOI: https://doi.org/10.1136/bmj-2022-073584
Cited by...
- Conflicted and confused? Health harming industries and research funding in leading UK universities
- Awareness and perceptions among members of a Japanese cancer patient advocacy group concerning the financial relationships between the pharmaceutical industry and physicians: a mixed-methods analysis of survey data
- Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies
- Sunshine on KOL : a retrospective study about financial ties between medical key opinion leaders and pharmaceutical industry in France
- Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
- Ultra-processed foods and the corporate capture of nutrition--an essay by Gyorgy Scrinis
- Covid-19: The lost lessons of Tamiflu
- Can covid-19 help us deal with the pandemic of defensive medicine?
- Commercial influence and covid-19
- Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study
- Financial ties between leaders of influential US professional medical associations and industry: cross sectional study
- Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
- Teaching students how to critically evaluate information from drug companies
- Independent information deserves more attention
- Taking legal action against improper disclosure of interests
- NoGrazie: an Italian initiative against commercial influence in health
- Distancing design of phase III trials from drug company influence